CDKN2D

CDKN2D（cyclin dependent kinase inhibitor 2D）は、ヒトではCDKN2D遺伝子にコードされるタンパク質である。p19INK4dの名称でも知られる。 CDKN2D遺伝子にコードされるタンパク質は、サイクリン依存性キナーゼ阻害因子のINK4ファミリーのメンバーである。このタンパク質はCDK4またはCDK6と安定な複合体を形成してCDKの活性化を妨げることで、細胞周期のG1期の進行を制御する細胞成長調節因子として機能する。この遺伝子の転写産物の存在量は細胞周期依存的に変動することが知られており、G1期の中盤が最も低く、S期に最大の発現となる。このタンパク質が関与する細胞周期の負の調節は、神経細胞の増殖や精子形成の抑制に関与することが示されている。この遺伝子には選択的スプライシングによる2種類の転写産物が存在するが、同一のタンパク質をコードする。 ヒトのCDKN2A遺伝子の代替的リーディングフレームの産物であるp14ARFに対応する、マウスのp19ARFと混同しないよう注意が必要である。 ^ a b c GRCh38: Ensembl release 89: ENSG00000129355 - Ensembl, May 2017 ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000096472 - Ensembl, May 2017 ^ Human PubMed Reference: ^ Mouse PubMed Reference: ^ “Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases”. Genomics 29 (3): 623–30. (Mar 1996). doi:10.1006/geno.1995.9957. PMID 8575754.  ^ a b “Entrez Gene: CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)”. 2021年12月3日閲覧。 “Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.”. Mol. Cell. Biol. 15 (5): 2672–81. (1995). doi:10.1128/MCB.15.5.2672. PMC 230497. PMID 7739547. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC230497/.  “Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4.”. Mol. Cell. Biol. 15 (5): 2682–8. (1995). doi:10.1128/MCB.15.5.2682. PMC 230498. PMID 7739548. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC230498/.  “Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.”. Mol. Biol. Cell 7 (1): 57–70. (1996). doi:10.1091/mbc.7.1.57. PMC 278612. PMID 8741839. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC278612/.  “Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells.”. Leukemia 11 (1): 54–63. (1997). doi:10.1038/sj.leu.2400522. PMID 9001419.  “Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.”. Nature 395 (6699): 237–43. (1998). doi:10.1038/26155. PMID 9751050.  “Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.”. Nature 395 (6699): 244–50. (1998). doi:10.1038/26164. PMID 9751051.  “Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.”. Structure 6 (10): 1279–90. (1998). doi:10.1016/S0969-2126(98)00128-2. PMID 9782052.  “Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.”. Oncogene 18 (9): 1663–76. (1999). doi:10.1038/sj.onc.1202466. PMID 10208428.  “Mutation testing in melanoma families: INK4A, CDK4 and INK4D.”. Br. J. Cancer 80 (1–2): 295–300. (1999). doi:10.1038/sj.bjc.6690354. PMC 2363010. PMID 10390011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363010/.  “Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases.”. Proc. Natl. Acad. Sci. U.S.A. 96 (23): 13462–7. (1999). doi:10.1073/pnas.96.23.13462. PMC 23970. PMID 10557343. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23970/.  “Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.”. FEBS Lett. 470 (2): 161–6. (2000). doi:10.1016/S0014-5793(00)01307-7. PMID 10734227.  “Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.”. Oncogene 19 (36): 4146–50. (2000). doi:10.1038/sj.onc.1203769. PMID 10962575.  “Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.”. Exp. Hematol. 29 (4): 490–8. (2001). doi:10.1016/S0301-472X(01)00619-1. PMID 11301189.  “Protein folding and stability of human CDK inhibitor p19(INK4d).”. J. Mol. Biol. 315 (3): 447–57. (2002). doi:10.1006/jmbi.2001.5242. PMID 11786024.  “Molecular cloning and characterization of the human p19(INK4d) gene promoter.”. FEBS Lett. 517 (1–3): 272–6. (2002). doi:10.1016/S0014-5793(02)02647-9. PMID 12062451.  “Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.”. Genes Chromosomes Cancer 35 (2): 176–81. (2002). doi:10.1002/gcc.10108. PMID 12203782.  “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. (2003). doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC139241/.  “Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.”. Nat. Biotechnol. 21 (5): 566–9. (2004). doi:10.1038/nbt810. PMID 12665801.  “Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.”. Br. J. Cancer 88 (8): 1277–80. (2004). doi:10.1038/sj.bjc.6600862. PMC 2747579. PMID 12698196. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747579/.  Overview of all the structural information available in the PDB for UniProt: P55273 (Cyclin-dependent kinase 4 inhibitor D) at the PDBe-KB.